Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 33.33% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at $26.0 million (down 33.33% YoY), while the FY2025 annual figure was $27.0 million, down 30.77% from the prior year.
• Other Non-Current Assets was $26.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $27.0 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $44.0 million in Q2 2025 to a low of $26.0 million in Q1 2026.
• Historically, Other Non-Current Assets has averaged $34.5 million across 5 years, with a median of $37.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets plunged 64.15% in 2022, then grew 8.33% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $38.0 million in 2022, then slipped by 5.26% to $36.0 million in 2023, then grew by 8.33% to $39.0 million in 2024, then plunged by 30.77% to $27.0 million in 2025, then fell by 3.7% to $26.0 million in 2026.
• The last three Other Non-Current Assets figures came in at $26.0 million (Q1 2026), $27.0 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.